Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumabtreated patients with advanced gastric cancer

In Japan, South Korea, and Taiwan, nivolumab might provide overall survival benefits
for patients with advanced gastric cancer. However, it is effective only in a limited
number of patients. The Glasgow prognostic score is an indicator of the systematic
inflammatory response and nutritional status. This study aimed to investigate the ability
of the Glasgow prognostic score and other markers to predict the outcomes of
patients treated with nivolumab. We reviewed the medical records of patients treated
for advanced gastric cancer and who received nivolumab between February 2015 and
June 2019 at Hyogo Cancer Center. The patients were categorized into two groups
according to their Glasgow prognostic scores. Overall, 53.3% and 46.7% of the
patients were assigned to groups with Glasgow prognostic scores of 0 and 1/2,
respectively. The median durations of progression-free and overall survival of the
participants were 2.3 and 5.7 months, respectively. The patients with a Glasgow
prognostic score of 0 had significantly higher median overall survival than those with
scores of 1 or 2 (16.4 vs. 4.2 months; p = 0.0006). This observation suggests that a
pretreatment Glasgow prognostic score of 0 is associated with better outcomes, and
this scoring system may be used as a predictor of outcomes in patients with advanced
gastric cancer treated with nivolumab.